This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

FEB 0 6 2001 Of Attorney Docket

Attorney Docket

Hon. Commissioner for Patents, Washington, D.C. 20231 on this 1st day of February, 2001.

(Signature of person mailing)
Deanna L. Miller

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark D. Fidock, et al

APPLICATION NO.: 09/663,542

FILING DATE: September 15, 2000

TITLE: Phosphodiesterase Enzymes

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

Ву

REQUEST FOR CORRECTED PROVISIONAL APPLICATION FILING RECEIPT

Please correct the filing receipt for the above-identified provisional patent application as follows:

Please see the attached copy of form Declaration for Utility or Design Patent Application (37 CFR 1.63, which lists not only Mark D. Fidock, but Nicola M. Robas as well. Please add Ms. Robas' name to the corrected Filing Receipt and send a copy at your earliest convenience.

A copy of the original filing receipt is attached upon which the above changes have been noted.

Date: 2/1/0

Respectfully submitted,


Gregory P. Raymer

Attorney for Applicant(s)

Reg. No. 36,647

Pfizer Inc.

Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-5746



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 09/663.542
 09/15/2000
 1638
 1264
 PC10349AGPR
 23
 8

CONFIRMATION NO. 3854

FILING RECEIPT

Gregg C Benson
Pfizer Inc
Patent Department
MS 4159 Eastern Point Road
Groton, CT 06340

OC00000005680032

Date Mailed: 01/16/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mark D. Fidock, Sandwich, UNITED KINGDOM;

Please add: Nicola M. Robas, UNITED KING DOM

Continuing Data as Claimed by Applicant

Foreign Applications

UNITED KINGDOM 9922124.4 09/17/1999

If Required, Foreign Filing License Granted 11/22/2000

Projected Publication Date:

Non-Publication Request: No

Early Publication Request: No

DEGET WED

JAN 2 2 2001

PATENT DEPT-GRTN

OPE - 1/24/01

Title

Phosphodiesterase enzymes

COPY TO NEW YORK 1-27

Preliminary Class

435

PEB 0 6 2001 CS 5

Data entry by : MASON, JAMES

Team : OIPE

Date: 01/16/2001

T DENNI KERBANIKAN KIRIN KARIK DINI DENGA DARIK BUMBANING MINI BINI DINI DENGA DARIK BERAKTIRA DARIK DENGA DARI

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on
 the Express-Mail-label.-If-there-is-a-discrepancy, you-should-submit-a-request_for_a_corrected_Eiling
 Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:



Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231